The Shareholders’ Meeting of Siegfried Holding AG today approved all proposals by the Board of Directors. It endorsed an unchanged distribution to the Shareholders of CHF 1.50 per share. The proposals regarding remuneration of the Board of Directors and Management have been approved.
Siegfried’s 112th Annual Shareholders’ Meeting took place in the Zofingen City Hall and was attended by around 210 shareholders and proxies representing about 50% of the shares. The Shareholders approved the following:
•The annual report, the financial statements and the consolidated financial statements for 2014; discharge of the members of the Board of Directors
• Appropriation of retained earnings to free reserves and distribution to shareholders from capital contribution reserves of CHF 1.50 per entitled registered share
• Proposals concerning maximum remuneration of Board members until the 2016 Shareholders Meeting, fixed remuneration of Executive Management for the 2016 financial year, short-term performance-related remuneration for the 2014 financial year and long-term performance-related remuneration of Executive Management for the current financial year in the form of entitlements
• The following members of the Board were elected for a further term: Colin Bond, Wolfram Carius, Andreas Casutt, Reto Garzetti and Thomas Villiger
• Re-election of Andreas Casutt as Siegfried Holding AG’s Chairman. Separate election of the Remuneration Committee consisting of Reto Garzetti and Thomas Villiger
• Appointment of BDO AG, Aarau, as independent proxy representative and PricewaterhouseCoopers AG, Basel, as auditors.
For further information:
Peter Gehler, Chief Communications Officer
peter.gehler@siegfried.ch
Phone +41 (0)62 746 11 48
Mobile +41 (0)79 416 41 16
Siegfried Holding AG
Untere Brühlstrasse 4
CH-4800 Zofingen
Tel. +41 (0)62 746 11 11
Fax +41 (0)62 746 11 03
www.siegfried.ch
About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta and in the USA. At the end of 2014, Siegfried reported annual sales of CHF 315 million and employs at the time being approximately 1400 employees. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.
Help employers find you! Check out all the jobs and post your resume.
